Quantcast

Latest Bite Stories

2010-03-22 07:00:00

BETHESDA, Md., March 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, announced today that 11 presentations will be made by the Company and its collaborators at the American Association for Cancer Research (AACR) 101st Annual Meeting to be held April 17-21, 2010 in Washington, DC. Presentation details: Poster Title: "Validation of...

ccb94156330a59ea6015b0da7f04d02e1
2010-03-19 09:05:06

Successful testing finally realizes decade-old theory Mosquitoes transmit infectious diseases to millions of people every year, including malaria for which there is no effective vaccine. New research published in Insect Molecular Biology reveals that mosquito genetic engineering may turn the transmitter into a natural 'flying vaccinator', providing a new strategy for biological control over the disease. The research, led by Associate Professor Shigeto Yoshida from the Jichi Medical University...

2010-03-17 09:50:00

BETHESDA, Md., March 17 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised in full their option to purchase an additional 1.5 million shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 per share. The Company received net proceeds from the offering of approximately $75.3...

2010-03-11 17:20:00

BETHESDA, Md., March 11 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) announced today the pricing of an underwritten public offering of 10 million shares of common stock at a public offering price of $7.00 per share. The Company has granted the underwriters a 30-day option to purchase an additional 1.5 million shares of common stock from the Company. All of the shares in the offering are being sold by Micromet. The closing of the offering is expected to take place on March 17,...

2010-03-09 15:01:00

BETHESDA, Md., March 9 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) announced today that it is offering to sell, subject to market and other conditions, 10 million shares of common stock in an underwritten public offering. In connection with the offering, the Company expects to grant the underwriters a 30-day option to purchase an additional 1.5 million shares of common stock from the Company. All of the shares in the offering are being offered by Micromet. Goldman, Sachs...

2010-03-04 06:30:00

BETHESDA, Md., March 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced its financial results for the fourth quarter and full year ended December 31, 2009. The Company also highlighted recent pipeline progress and outlined expected 2010 milestones. "With our lead product candidate blinatumomab expected to begin a European pivotal...

2010-02-25 15:02:00

BETHESDA, Md., Feb. 25 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that the Company will participate in the 2010 RBC Capital Markets Healthcare Conference, to be held March 2 - 3, 2010 in New York City. Christian Itin, Ph.D., the Company's President and CEO, will participate in a panel discussion titled New Targets in Cancer Therapy on March 2, 2010 at 8:00 AM ET. The panel discussion will be webcast live and may be accessed at:...

2010-02-25 15:01:00

BETHESDA, Md.,, Feb. 25 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will host a conference call and audio webcast to review its fourth quarter and full year 2009 results on Thursday, March 4, 2010, at 8:30 AM ET. To participate in the conference call, please dial 800-659-1942 (domestic) or 617-614-2710 (international) and reference the access code 85243244. The presentation will be available via webcast at...

2010-02-10 10:00:00

BETHESDA, Md., Feb. 10 /PRNewswire-FirstCall/ -- At its annual investor R&D Day today, Micromet, Inc. (Nasdaq: MITI) outlined the design of a registration study for the Company's lead product candidate blinatumomab in acute lymphocytic leukemia (ALL), highlighted clinical data demonstrating the breadth of blinatumomab's activity in B-cell non-Hodgkin's lymphomas and announced plans to expand clinical development of blinatumomab in the U.S. "We are very pleased with the strong support...

2010-02-04 07:01:00

BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced that it will host a Research & Development Day for the investment community on Wednesday, February 10, 2010 from 8:00 AM - 11:00 AM ET at the Yale Club in New York City. Members of the Company's leadership team will outline near-term development plans for the Company's lead product candidate blinatumomab (MT103) and will provide an update on the Company's earlier stage BiTE®...


Latest Bite Reference Libraries

0_e288c9a7e7e932afbeba3516c20e64f2
2009-06-16 22:38:30

The Brown Recluse Spider (Loxosceles reclusa) is a species of arachnid that is native to the USA from the southern Midwest south to the Gulf of Mexico. It can be found in Canada as well around southeast Ontario, and southern Quebec. Its range lies from southeastern Nebraska through southern Iowa, Illinois, and Indiana to southwestern Ohio. In the south, it is native from central Texas to western Georgia. It is not usually found west of the Rocky Mountains. Contrary to popular belief, this...

More Articles (1 articles) »
Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related